Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

6 ML RADIUM CHLORIDE RA-223 30 MCI/ML Injection [Xofigo]

Known as: Xofigo 1100 kBq/ML in 6 ML Injection, Xofigo (radium Ra-223 dichloride) 6600 kBq per 6 ML Injection, RADIUM RA-223 DICHLORIDE 30 uCi in 1 mL INTRAVENOUS INJECTION [Xofigo] 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Background and Objective: Radium-223 dichloride (Xofigo®) is a calcium mimetic agent approved for the treatment of castration… Expand
  • table 1
  • table 2
Review
2017
Review
2017
Prostate cancer is the most common malignant disease in men. Several therapeutic agents have been approved during the last 10… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 3
2017
2017
The integrity of the genome of eukaryotic cells is secured by complex signaling pathways, known as DNA damage response (DDR… Expand
2017
2017
ZusammenfassungAlpharadin (223Radiumdichlorid/Xofigo®) ist ein seit November 2013 zur Therapie des fortgeschrittenen… Expand
2016
2016
Radium-223 dichloride (Xofigo®; 223Ra) is an alpha-emitting radiopharmaceutical FDA-approved for the treatment of bone metastases… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2015
Review
2015
Objectives: Prostate cancer (PC) is the most common cancer in Western countries. Recent advances in the treatment of metastatic… Expand
  • table 1
  • table 2
  • table 3
2015
2015
Prostate cancer (PC) is the most common neoplasm in men in Western countries, and approximately 10 – 20 % of patients with PC… Expand
Review
2014
Review
2014
Radium-223 dichloride (Xofigo®; formerly Alpharadin™) [hereafter referred to as radium-223] is a first-in-class alpha particle… Expand
  • table 1
  • figure 2
2014
2014
In patients with advanced castration-resistant prostate cancer (CRPC), symptomatic bone metastases are frequently present. Xofigo… Expand